𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reduction of liver stiffness by antiviral therapy in chronic hepatitis B

✍ Scribed by Keisuke Osakabe; Naohiro Ichino; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Shiho Kitahara; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Yuko Arima; Koji Suzuki; Kentaro Yoshioka

Publisher
Springer Japan
Year
2011
Tongue
English
Weight
356 KB
Volume
46
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Endpoints of therapy in chronic hepatiti
Endpoints of therapy in chronic hepatitis B
✍ Jordan J. Feld; David K. H. Wong; E. Jenny Heathcote πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

Because clearance of hepatitis B virus (HBV) infection is rarely, if ever, achievable, the goals of therapy necessarily focus on prevention of bad clinical outcomes. Ideally, therapies would be shown to prevent tangible clinical endpoints like development of cirrhosis, end-stage liver disease and he

Association of intrahepatic cccDNA reduc
Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents
✍ Pin-Nan Cheng; Wen-Chun Liu; Hung-Wen Tsai; I-Chin Wu; Ting-Tsung Chang; Kung-Ch πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 109 KB

Covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is difficult to eradicate using current antiviral therapy. This study compares cccDNA reduction with relation to liver histology in nucleoside/nucleotide-naΔ± Β¨ve chronic hepatitis B patients receiving oral antiviral monotherapy (n ΒΌ

Lamivudine plus interleukin-12 combinati
Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity
✍ Eirini I. Rigopoulou; Deepak Suri; Shilpa Chokshi; Ivana Mullerova; Steven Rice; πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 381 KB

Interleukin-12 (IL-12) is an immunomodulatory cytokine that promotes cellular immunity. Pre-clinical data suggest that IL-12 inhibits hepatitis B virus (HBV) replication by stimulating interferon-gamma (IFN-gamma) production. We investigated whether a combination treatment with lamivudine plus recom

Clearance of serum HBsAg and anti-HBs se
Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B
✍ Olivier Borgniet; Parviz Parvaz; CΓ©cile Bouix; Philippe Chevallier; Christian Tr πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 151 KB

## Abstract In this study, we have analyzed the evolution of serum HBsAg levels in 16 patients with chronic hepatitis B who showed an HBsAg seroconversion following antiviral therapy. The data showed that the clearance of serum HBsAg is slower than that of serum HBV DNA, which may reflect a slow ki